Middle East and Africa Phentermine Hydrochloride Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Capsules, Orally Disintegrating Tablets (ODT), Extended-Release Formulations), By Strength (8 mg, 15 mg, 18.75 mg, 30 mg), By Country (Brazil, Mexico, Argentina, Chile, Colombia) and Forecast, 2026-2034

Middle East and Africa Phentermine Hydrochloride Market Trends

Digital obesity care and oral-treatment convenience reshape prescribing pathways

Obesity treatment is increasingly integrated with telehealth, digital prescribing, remote follow-up, and structured weight-management services. Globally, 2.5 billion adults were overweight in 2022, including more than 890 million living with obesity; 43% of adults were overweight and approximately 16% had obesity. These figures create a substantial addressable treatment population for pharmacological and non-pharmacological interventions.

Oral therapies retain convenience advantages as the obesity-treatment environment expands toward newer pharmacological classes. Phentermine hydrochloride products are available in strengths including 8 mg, while current U.S. labeling identifies oral administration and Schedule IV status for Lomaira.

Middle East and Africa Phentermine Hydrochloride Market Drivers

High obesity prevalence expands the medically eligible treatment population

Demand is supported by substantial obesity prevalence across major Middle Eastern economies. Referenced 2024 estimates place adult obesity prevalence at approximately 35.4% in Saudi Arabia, 32.1% in Turkey, 32.0% in Egypt, and 31.7% in the UAE.

Middle East and Africa Phentermine Hydrochloride Market Restraints

Regulatory Restrictions and Competition from Newer Obesity Therapies

Strict prescription controls, varying pharmaceutical regulations, and the growing preference for newer anti-obesity therapies can restrain the adoption of phentermine hydrochloride across the Middle East and Africa. In the UAE, prescription medical products are subject to controlled dispensing and marketing requirements, while products requiring prescriptions cannot be freely marketed or sold by non-pharmaceutical establishments. At the same time, the regional obesity-treatment landscape is shifting toward newer therapies; the UAE approved an oral GLP-1 treatment in 2026, while South Africa has experienced rapid adoption of GLP-1 therapies, with Mounjaro reaching 52% market share in January 2026. These developments can reduce the relative attractiveness of older sympathomimetic appetite suppressants and increase regulatory, clinical, and competitive pressure on phentermine-based products, restraining the Middle East and Africa Phentermine Hydrochloride Market.

Middle East and Africa Phentermine Hydrochloride Market Opportunities

Telehealth, specialist clinics and convenient oral formulations widen access

Digitally enabled obesity programs provide an opportunity to connect prescription management with nutritional counseling and longitudinal monitoring. With more than 890 million adults globally living with obesity in 2022 and adult obesity prevalence having more than doubled since 1990, the treatment ecosystem is moving toward scalable chronic-weight-management models.

Challenges in Middle East and Africa Phentermine Hydrochloride Market

Uneven healthcare access and rapidly evolving obesity pharmacotherapy complicate commercialization

Market participants face heterogeneous prescribing rules, controlled-drug requirements, reimbursement conditions, and access to specialist obesity care. Africa simultaneously faces nutritional inequality: recent UN-linked reporting indicated that 66.6% of Africa's population could not afford a healthy diet, while global obesity increased from 12.1% in 2012 to 16.2% in 2024. This coexistence of obesity and affordability constraints increases the importance of pricing, generic availability, physician oversight, and sustainable patient-access models.

Middle East and Africa Phentermine Hydrochloride Market Segmentation

The market is segmented by dosage form, strength, route of administration, distribution channel, application, end user, and sales type. Among categories supported by the supplied numerical dataset, tablets lead dosage forms with approximately 40.46% of 2026 revenue, followed by capsules at 32.38%, ODTs at 17.00%, and extended-release formulations at 10.16%.

By Dosage Form

Tablets represent the largest dosage-form category, increasing from USD 26.93 million in 2025 to USD 28.91 million in 2026 and USD 51.03 million by 2034 at a 7.36% CAGR. Their 2026 contribution is approximately 40.46% of the supplied dosage-form total of USD 71.46 million.

Capsules are the fastest-growing category at a 7.58% CAGR and are forecast to reach USD 41.52 million in 2034. ODTs expand at 6.80%, while extended-release formulations advance at 6.98%, demonstrating positive growth across all four supplied formulation categories.

By Strength

The market covers 8 mg, 15 mg, 18.75 mg, 30 mg, and 37.5 mg strengths. Commercial availability of 8 mg phentermine hydrochloride tablets demonstrates the role of lower-dose oral formulations, while higher strengths support physician-selected treatment regimens. Route-specific market values and CAGRs were not included in the mandatory dataset.

By Distribution Channel

Hospital pharmacies, retail pharmacies, online pharmacies, and weight-loss clinics comprise the distribution structure. The expansion of digital obesity management supports online and telehealth-linked dispensing pathways, while controlled prescription requirements preserve the importance of regulated pharmacy channels. No channel-level USD values or CAGR figures were supplied.

By Application

Applications comprise obesity at BMI ≥30 and overweight at BMI ≥27 with associated conditions such as hypertension or diabetes. WHO defines adult obesity at BMI ≥30 and overweight at BMI ≥25; approximately 890 million adults globally were living with obesity in 2022. Application-specific revenue and CAGR data were not supplied.

By End User

Hospitals, ambulatory surgical centers, specialty weight-loss clinics, and homecare/telehealth users constitute the end-user categories. Specialty clinics and telehealth models are positioned around recurring weight assessment and prescription follow-up, whereas hospitals serve patients with more complex comorbidity profiles. No end-user numerical split was provided.

By Sales Type

Branded and generic drugs form the sales-type segmentation. Generic competition is important for affordability, while branded formulations can differentiate through dosing formats and physician familiarity. Current labeling confirms commercially marketed 8 mg phentermine hydrochloride tablets in multiple package counts.

Middle East and Africa Phentermine Hydrochloride Market Outlook

The requested Brazil, Mexico, Argentina, Chile, and Colombia geography is outside the Middle East and Africa scope and has no supplied mandatory dataset. Accordingly, the regional analysis uses the six countries actually contained in the provided Middle East and Africa table rather than fabricating Latin American values.

United Arab Emirates

The UAE leads with USD 36.74 million in 2026, approximately 51.47% of the supplied country total, rising to USD 64.36 million by 2034 at 7.26% CAGR. Its 2025 value was USD 34.25 million. Adult obesity prevalence estimates around 31.7% provide a substantial clinical demand base.

Saudi Arabia

Saudi Arabia contributes USD 13.87 million in 2026, or approximately 19.43%, and is forecast to reach USD 23.52 million in 2034 at 6.83% CAGR. Its 2025 value was USD 12.98 million, while referenced adult obesity prevalence stands near 35.4%.

South Africa

South Africa accounts for USD 5.74 million in 2026, approximately 8.04% of the supplied country total, compared with USD 5.35 million in 2025. Revenue is forecast at USD 10.02 million by 2034, representing a 7.22% CAGR.

Egypt

Egypt generates USD 5.74 million in 2026, approximately 8.04% of the country total, and reaches USD 10.11 million by 2034. Its 7.33% CAGR is the fastest among the six supplied countries, supported by a large population and adult obesity prevalence estimated near 32.0%.

Nigeria

Nigeria advances from USD 5.11 million in 2025 to USD 5.48 million in 2026 and USD 9.62 million in 2034. The country contributes approximately 7.68% in 2026 and records a 7.28% CAGR, the second-fastest rate among the supplied national markets.

Turkey

Turkey represents USD 3.81 million in 2026, approximately 5.34% of the supplied total, versus USD 3.56 million in 2025. Revenue is projected to reach USD 6.63 million in 2034 at 7.16% CAGR; referenced adult obesity prevalence is approximately 32.1%.

Top players in Middle East and Africa phentermine hydrochloride market

1. KVK-Tech, Inc.
2. Calvin Scott & Co., Inc.
3. Teva Pharmaceutical Industries Ltd.
4. Sandoz Group AG
5. Amneal Pharmaceuticals, Inc.
6. Sun Pharmaceutical Industries Ltd.
7. Viatris Inc.
8. Hikma Pharmaceuticals PLC
9. Aurobindo Pharma Limited
10. Dr. Reddy's Laboratories Ltd.
11. Lannett Company, Inc.
12. Alvogen

Top Two Companies

• KVK-Tech, Inc.

KVK-Tech has an established position in phentermine hydrochloride manufacturing, including production of the 8 mg Lomaira formulation. Current labeling identifies 30-, 60-, 90-, 250-, and 500-tablet package configurations and confirms oral administration and Schedule IV classification.

• Teva Pharmaceutical Industries Ltd. 

Teva participates broadly in global generic pharmaceuticals and represents a relevant competitive benchmark in established small-molecule prescription markets. However, the supplied mandatory tables contain no company-level revenue, shipment, or prescription data. Consequently, assigning a numerical percentage to Teva would create an unsupported estimate; company positioning should instead be assessed through product availability, regulatory registrations, pricing, distribution coverage, and generic competition.

Recent Developments in Middle East and Africa Phentermine Hydrochloride Market

• 2026: DailyMed labeling revised in May 2026 continued to identify Lomaira as an 8 mg phentermine hydrochloride oral Schedule IV prescription tablet manufactured by KVK-Tech.
• 2025: WHO reported that 2.5 billion adults were overweight in 2022, including more than 890 million living with obesity, reinforcing the expanding global clinical burden addressed by weight-management therapies.
• 2025: Oral next-generation obesity medicines progressed as an important competitive technology category, highlighting increasing pharmaceutical investment in convenient non-injectable weight-management options.

Research Methodology

The analysis uses the user-supplied 2025, 2026, and 2034 country and dosage-form tables as the primary quantitative source. Country shares were calculated against the supplied 2026 total of USD 71.38 million, while dosage-form contributions were calculated against the corresponding USD 71.46 million total. Supplied CAGRs—including 7.2% for the country dataset and 7.18% for the dosage-form dataset—were retained without alteration. Secondary evidence was used only for market context, obesity prevalence, product characteristics, and competitive developments. No unsupported segment, company, production-volume, or country revenue figures were fabricated where source data were unavailable.